

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT7158581

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	ASSIGNMENT	
CONVEYING PARTY DATA		
	Name	Execution Date
	NOVARTIS AG	06/15/2016
RECEIVING PARTY DATA		
Name:	GLAXOSMITHKLINE BIOLOGICALS SA	
Street Address:	RUE DE L'INSTITUT 89	
City:	RIXENSART	
State/Country:	BELGIUM	
Postal Code:	1330	
PROPERTY NUMBERS Total: 6		
Property Type	Number	
Application Number:	17560019	
Application Number:	17560052	
Application Number:	17560059	
Application Number:	17560116	
Application Number:	17560138	
Application Number:	17560092	
CORRESPONDENCE DATA		
Fax Number:	(949)760-9502	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
Phone:	9497600404	
Email:	efiling@knobbe.com	
Correspondent Name:	MICHAEL L. FULLER	
Address Line 1:	KNOBBE MARTENS	
Address Line 2:	2040 MAIN STREET, 14TH FLOOR	
Address Line 4:	IRVINE, CALIFORNIA 92614	
ATTORNEY DOCKET NUMBER:	GSK.028C1/C4/D1/D2/D3/D4	
NAME OF SUBMITTER:	MICHAEL L FULLER	
SIGNATURE:	/Michael L Fuller/	
DATE SIGNED:	02/03/2022	

Total Attachments: 2

source=US13808080-assignment_3#page1.tif

source=US13808080-assignment_3#page2.tif

CONFIRMATORY ASSIGNMENT

WE, **NOVARTIS AG** a company limited by shares duly incorporated in Switzerland and whose registered office is at Lichtstrasse 35, 4056 Basel, Switzerland do hereby declare that we are the sole owner of the following patents/ patent applications entitled "LIPOSOMES WITH LIPIDS HAVING AN ADVANTAGEOUS PKA- VALUE FOR RNA DELIVERY".


Country	Application Date	Application Number	Grant Date	Patent Number
Albania	06-Jul-11	AL/P/2016/6	28-Oct-15	5609
Australia	06-Jul-11	2011276234		
Austria	06-Jul-11	11736500 7	28-Oct-15	EP2590626
Belgium	06-Jul-11	11736500 7	28-Oct-15	EP2590626
Brazil	06-Jul-11	BR1120130002441		
Bulgaria	06-Jul-11	11736500 7	28-Oct-15	EP2590626
Canada	06-Jul-11	2804396		
China P R	06-Jul-11	201180042459 2	25-Nov-15	ZL201180042459 2
Croatia	06-Jul-11	P20151349	28-Oct-15	EP2590626
Cyprus	06-Jul-11	CY20151101165	28-Oct-15	EP2590626
Czech Republic	06-Jul-11	11736500 7	28-Oct-15	EP2590626
Denmark	06-Jul-11	11736500 7	28-Oct-15	EP2590626
European Patent Convention	06-Jul-11	11736500 7	28-Oct-15	EP2590626
Estonia	06-Jul-11	11736500 7	28-Oct-15	EP2590626
Finland	06-Jul-11	11736500 7	28-Oct-15	EP2590626
France	06-Jul-11	11736500 7	28-Oct-15	EP2590626
United Kingdom	06-Jul-11	11736500 7	28-Oct-15	EP2590626
Germany	06-Jul-11	EP2590626	28-Oct-15	602011021006 8
Greece	06-Jul-11	11736500 7	28-Oct-15	EP2590626
Hungary	06-Jul-11	11736500 7	28-Oct-15	EP2590626
Iceland	06-Jul-11	11736500 7	28-Oct-15	EP2590626
India	06-Jul-11	4161/KOLNP/2012		
Ireland	06-Jul-11	11736500 7	28-Oct-15	EP2590626
Italy	06-Jul-11	502016000000474	28-Oct-15	EP2590626
Japan	06-Jul-11	2013-518814		
Latvia	06-Jul-11	11736500 7	28-Oct-15	EP2590626
Lithuania	06-Jul-11	11736500 7	28-Oct-15	EP2590626
Luxembourg	06-Jul-11	11736500 7	28-Oct-15	EP2590626
Macedonia	06-Jul-11	MK/P/2015/666	28-Oct-15	EP2590626
Malta	06-Jul-11	11736500 7	28-Oct-15	EP2590626
Mexico	06-Jul-11	MX/A/2013/000164	24-Sep-15	333446
Monaco	06-Jul-11	11736500 7	28-Oct-15	EP2590626
Netherlands	06-Jul-11	11736500 7	28-Oct-15	EP2590626
Norway	06-Jul-11	11736500 7	28-Oct-15	EP2590626
Poland	06-Jul-11	11736500 7	28-Oct-15	EP2590626
Portugal	06-Jul-11	11736500 7	28-Oct-15	EP2590626
Romania	06-Jul-11	11736500 7	28-Oct-15	EP2590626
Russian Federation	06-Jul-11	2013104878		

San Marino	06-Jul-11	11736500 7	28-Oct-15	SM-T-201600007
Switzerland	06-Jul-11	11736500 7	28-Oct-15	EP2590626
Serbia	06-Jul-11	P-880/15	28-Oct-15	EP2590626
Slovenia	06-Jul-11	11736500 7	28-Oct-15	EP2590626
Slovak Republic	06-Jul-11	11736500 7	28-Oct-15	EP2590626
Spain	06-Jul-11	11736500 7	28-Oct-15	EP2590626
Sweden	06-Jul-11	11736500 7	28-Oct-15	EP2590626
Turkey	06-Jul-11	TR201600093T4	28-Oct-15	EP2590626
United States	06-Jul-11	13/808080		

And in accordance with the Intellectual Property Assignment Agreement dated 2 March 2015 between **NOVARTIS AG** and **GLAXOSMITHKLINE BIOLOGICALS SA**, for good and valuable consideration, the receipt of which is hereby acknowledged, we **NOVARTIS AG** have assigned the entire right, title and interest and from which priority may be claimed from one or more applications, or any division, continuation and continuation-in-part of said application to in and to said patent application and all countries in which this/ these application(s) are filed to **GLAXOSMITHKLINE BIOLOGICALS SA** of Rue de l'Institut 89, 1330 Rixensart, Belgium


Dated this 15 day of June 2016

Signed for and on behalf of
NOVARTIS AG


Lorraine B. Ling
Authorized Signatory on behalf of
NOVARTIS AG


Theodore R. Furman
Authorized Signatory on behalf of
NOVARTIS AG

Signed for and on behalf of
GLAXOSMITHKLINE BIOLOGICALS SA


William R. Majarian
Authorized Official on behalf of
GLAXOSMITHKLINE BIOLOGICALS SA